首页> 中文期刊> 《动物医学进展》 >鸡传染性鼻炎和新城疫二联灭活疫苗的研究

鸡传染性鼻炎和新城疫二联灭活疫苗的研究

         

摘要

A combined infectious coryza and newcastle disease inactivated vaccine was developed using page's serovar A ,B and C of Avibacterium paragallinarum (Avpg) and La Sota strain of NDV .Three batch of vaccines were used for safety test ,The Chicken were injected 0 .5 mL/chicken at a time for three times and 2 .0 mL/chicken at a time .We carry out vaccine efficacy experiment with three batches of vaccines for SPF chicken ,30 days after immunization ,the chickens were challenged with Page's serovar A ,B and C of Avpg .The immune duration test of the conventional chickens which were immunized at 42 days‐old and 110 days‐old .Nine months after second immunization ,the chickens were challenged with Page's A ,B ,C of Avpg and virulent Newcastle Disease virus .The effect of storage on the vaccine was evaluated in SPF chickens using three batches of vaccine stored at 4 ℃‐8 ℃ for 12 and 15 months .The result show that the vaccines is very safe ,and challenged protection rate of immunized SPF chickens is ≥ 80% for Page's sero‐var A ,B and C of Avpg .HI titer of ND is great than 24 for immunized SPF chickens using 20 μL vaccine . The conventional chickens were challenged at 9 months post second vaccination and the protection rate ≥70% for all three serovars ,and 100% against the virulent Newcastle Disease virus .The protection rate of immunized chickens using the vaccine stored at 4 ℃‐8 ℃ for 12 and 15 months is ≥70% for Page's serovar A ,B and C of Avpg .,HI titer is great than 24 and 7/10 against the virulent Newcastle Disease virus .The vaccine is safe and effective .%利用Page A型、B型、C型副鸡禽杆菌和新城疫病毒La Sota株,研制鸡传染性鼻炎(三价)和新城疫二联油乳剂灭活疫苗。用3个批次疫苗进行单剂量(0.5mL/次)3次接种和大剂量(2.0mL)单次接种的安全性试验、SPF鸡的免疫效力试验、商品鸡的免疫持续期试验和疫苗的保存期试验。结果表明,3批疫苗对试验鸡安全无副作用;免疫SPF鸡只30 d后对A、B、C型副鸡禽杆菌攻毒的保护率≥80%,用20μL/只疫苗免疫SPF鸡21 d后新城疫病毒的平均HI抗体>24;商品鸡42日龄首免,110日龄二免,二免后9个月对A、B、C型副鸡禽杆菌攻毒的保护率≥70%,对新城疫病毒强毒100%保护;用4℃~8℃保存12个月和15个月的3批疫苗进行了SPF鸡的近期免疫效力试验,结果对A、B、C型副鸡禽杆菌攻毒的保护率≥70%,用20μL/只疫苗免疫SPF鸡,免疫后21 d新城疫病毒的平均 HI抗体>24,对新城疫病毒强毒的攻毒保护率>70%。研制的疫苗安全有效。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号